TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31820121
Drug: Risedronate (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (35 mg) alone
Study: 17550040
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied vitamin 'E' (100 mg twice daily)
Study: 17550040
Drug: Systemically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemically administered vitamin 'E'
Study: 15970639
Drug: Nasal rinsing
Normalized name: MedActive Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal rinsing with hypertonic saline (3 times daily for 7 weeks)
Study: 10073976
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use with factor II:A20210
Study: 10073976
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use with factor V:A1691
Study: 1959365
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (7 mg in 14 mL of sterile saline)
Study: 1959365
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline 14 mL)
Study: 28378356
Drug: Processed Nigella
Normalized name: Nigella sativa seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Processed Nigella sativa seed powder (2 g/day in divided doses)
Study: 20595643
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (2 capsules and 4 cups water/d)
Study: 20605696
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (4 cups water/d)
Study: 17692724
Drug: Garenoxacin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garenoxacin (oral or intravenous) 50-1200 mg/d for 1 to 28 days
Study: 15453552
Drug: Control oral
Normalized name: Dayquil Mucus Control Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oral appliance
Study: 9802141
Drug: Ramipril 10
Normalized name: ramipril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 10 mg o.d.
Study: 7543352
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of rhGM‐CSF, 250 micrograms/m2/day (trial 1)
Study: 7543352
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of rhGM‐CSF, 250 micrograms/m2/day (trial 2)
Study: 2083956
Drug: Nebuhaler (conical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler (conical spacer with inhalation valve)
Study: 28429365
Drug: Screwed implant-abutment
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Screwed implant-abutment connection (Group 1)
Study: 28429365
Drug: Cemented implant-abutment
Normalized name: Cement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cemented implant-abutment connection (Group 2)
Study: 26027630
Drug: Alirocumab (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab (75 mg every 2 weeks, increased to 150 mg Q2W at week 12 if LDL-C ≥70 mg/dL)
Study: 23529851
Drug: Group HDO
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group HDO (haloperidol 2 mg, dexamethasone 8 mg, ondansetron)
Study: 24565295
Drug: Group O
Normalized name: plasma, human, blood group O
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group O (ondansetron 8 mg)
Study: 18795629
Drug: Tamsulosin (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.4 mg, once daily) after ESWL
Study: 8630960
Drug: Chamomile mouthwash,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chamomile mouthwash, administered thrice daily for 14 days.
Study: 8630960
Drug: Placebo mouthwash,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo mouthwash, administered thrice daily for 14 days.
Study: 10149894
Drug: Hercules injections
Normalized name: Hercules Club Whole
DrugBank: Zanthoxylum clava-herculis whole (DB14353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hercules injections
Study: 10149894
Drug: Conventional manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional manual injections
Study: 31436395
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care (SoC; intensive chemotherapy)
Study: 27553751
Drug: Subcutaneous mepolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous mepolizumab treatment
Study: 20929607
Drug: Plasma kallikrein
Normalized name: Plasma kallikrein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma kallikrein inhibitor
Study: 20929607
Drug: Bradykinin B₂‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bradykinin B₂‐receptor antagonist
Study: 12679754
Drug: Clopidogrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel + Aspirin
Study: 18232183
Drug: Miglitol 50
Normalized name: miglitol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miglitol 50 mg three times daily for 12 weeks
Study: 3700932
Drug: Doxepin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin (10 to 20 mg daily)
Study: 25164259
Drug: Group-based dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based dietary intervention (individualized calorie goals, weight maintenance advice, Dietary Approaches to Stop Hypertension dietary pattern, weekly group meetings)
Study: 23866514
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (120 mg daily dose)
Study: 23866514
Drug: Rivastigmine (4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (4.5 mg daily dose)
Study: 18785988
Drug: LAB4 multistrain
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAB4 multistrain probiotic preparation (2.5 × 10(10) cfu/capsule)
Study: 17468062
Drug: Intravenous zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous zoledronic acid (ZOL) 5 mg
Study: 17468062
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 70 mg
Study: 8116042
Drug: Adjunct treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct treatment with 10 courses of photochemotherapy (PCT)
Study: 8116042
Drug: Adjunct treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct treatment with 20 courses of photochemotherapy (PCT)
Study: 8116042
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no additional treatment
Study: 3136642
Drug: High lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: High lysine (206 mg.kg‐1.d‐1)
Study: 3136642
Drug: Low lysine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low lysine (158 mg.kg‐1.d‐1)
Study: 3136642
Drug: High threonine
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High threonine (147 mg.kg‐1.d‐1)
Study: 3136642
Drug: Low threonine
Normalized name: Threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low threonine (113 mg.kg‐1.d‐1)
Study: 3136642
Drug: High histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High histidine (124 mg.kg‐1.d‐1)
Study: 3136642
Drug: Low histidine
Normalized name: Histidine
DrugBank: Histidine (DB00117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low histidine (85 mg.kg‐1.d‐1)
Study: 31361922
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (ZOL) 5 mg annually
Study: 21788827
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation therapy on tissue expanders (group 2)
Study: 21788827
Drug: Postmastectomy radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postmastectomy radiation therapy on permanent implants (group 1)
Study: 14627176
Drug: losartan/HCTZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan/HCTZ (50 mg/12.5 mg)
Study: 11128853
Drug: Running for
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in lower leg muscles increased from 24.6 +/- 9.5% to 43.1 +/- 4.7%; P < 0.05
Study: 11128853
Drug: Running for
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in heart increased from 2.3 +/- 0.4% to 2.8 +/- 0.6%; P < 0.05
Study: 11128853
Drug: Resting for
Normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Resting for 35 min after FDG injection; FDG uptake in abdominal region reduced from 37.3 +/- 7.2% to 19.7 +/- 4.9%; P < 0.05
Study: 11128853
Drug: Running for
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Running for 35 min with FDG injection after 15 min; FDG uptake in brain remained stable at 11.9 +/- 2.8% at rest and 10.3 +/- 2.5% after exercise; P not specified
Study: 9175961
Drug: Combined spinal-extradural
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined spinal-extradural technique with 2.25 ml of 0.5% hyperbaric bupivacaine
Study: 3083995
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg prednisolone daily
Study: 3083995
Drug: 0.4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg/kg prednisolone daily
Study: 3083995
Drug: 0.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/kg prednisolone daily
Study: 26924243
Drug: Camicinal 125
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 125 mg
Study: 26924243
Drug: Camicinal 25
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 25 mg
Study: 28782145
Drug: Camicinal 50
Normalized name: Camicinal
DrugBank: Camicinal (DB12567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camicinal 50 mg
Study: 23801256
Drug: Aripiprazole (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (mean dose 5.5 mg/day)
Study: 23801256
Drug: Risperidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (mean dose 1.12 mg/day)
Study: 20082200
Drug: Intraoperative orbital
Normalized name: barbital
DrugBank: Barbital (DB01483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative orbital floor triamcinolone acetonide (1 ml = 40 mg)
Study: 20082200
Drug: 4‐week postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐week postoperative oral prednisolone
Study: 19013239
Drug: 0.3% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3% DHEA cream
Study: 19013239
Drug: 1% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% DHEA cream
Study: 19013239
Drug: 2% DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% DHEA cream
Study: 19013239
Drug: Topical DHEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical DHEA
Study: 19013239
Drug: Placebo (0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0% DHEA cream)
Study: 15907404
Drug: Lacidipine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (4 mg/day, n = 48)
Study: 10721943
Drug: Primary adjuvant
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary adjuvant therapy
Study: 14724725
Drug: Continuous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous lateral rotational therapy (CLRT)
Study: 2019190
Drug: Conventional bed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bed treatment (turned every 2 hours)
Study: 2019190
Drug: Conventional bed
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional bed treatment
Study: 6290435
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg oral
Study: 28874171
Drug: Galium‐Heel® (low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galium‐Heel® (low‐dose multicomponent medicine) administered twice a day for six non‐consecutive months
Study: 28874171
Drug: Galium‐Heel® (low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galium‐Heel® (low‐dose multicomponent medicine)
Study: 19268614
Drug: Tailored behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored behavioural treatment protocol (TBT)
Study: 19268614
Drug: Exercise based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise based physical therapy protocol (EBT)
Study: 14707796
Drug: Birth weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Birth weight <3000 g
Study: 9885731
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with grass pollen extract (9,500 BU/ml)
Study: 8004299
Drug: Nebulized albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized albuterol (5 mg x 2)
Study: 8004299
Drug: Intravenous albuterol
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous albuterol (0.5 mg)
Study: 2591460
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g Heptaminol Adenosine Phosphate (HAP)
Study: 1242861
Drug: Beclomethasone Dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone Dipropionate (12 metered-doses per day)
Study: 1242861
Drug: Dexamethasone Isonicotinate
Normalized name: Dexamethasone isonicotinate
DrugBank: Dexamethasone isonicotinate (DB11487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone Isonicotinate (12 metered-doses per day)
Study: 31821452
Drug: Amoxicillin (7-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (7-day therapy)
Study: 31775353
Drug: Supplement A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement A (50 mg of blackcurrant anthocyanin)
Study: 31775353
Drug: Supplement B
Normalized name: Lipotropic Adju Lipot Supplement B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement B (50 mg of blackcurrant anthocyanin plus vitamin E)
Study: 27128218
Drug: AZD7325 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 2 mg
Study: 27128218
Drug: AZD7325 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD7325 10 mg
Study: 17989272
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi Chuan twice a week for 16 weeks
Study: 14508838
Drug: Standard fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fractionated radiation treatment arm
Study: 14508838
Drug: Hyperfractionated radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyperfractionated radiation treatment arm
Study: 11199361
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg once daily (QD)
Study: 11199361
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg twice daily (BID)
Study: 11199361
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily (QD)
Study: 1589586
Drug: Lithium (steady-state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (steady-state serum levels 0.9-1.3 mEq/L)
Study: 27760998
Drug: febuxostat 40 mg
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: febuxostat 40 mg
Study: 27760998
Drug: benzbromarone 50 mg
Normalized name: benzbromarone
DrugBank: Benzbromarone (DB12319)
Approvals — FDA: no, EMA: no, PMDA: no
Description: benzbromarone 50 mg
Study: 27760998
Drug: febuxostat 20 mg
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: febuxostat 20 mg and benzbromarone 25 mg (feb/ben)
Study: 25645166
Drug: Control activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control activity (e.g., reading newspaper)
Study: 18181335
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (10 mg every 20 minutes, max 40 mg in the first hour, then 20 mg every 4 hours for up to 72 hours)
Study: 18181335
Drug: Intravenous terbutaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous terbutaline (initially infused at 10 microg/min, increased to max 25 microg/min, then switched to subcutaneous injection of 0.25 mg every 4 hours for 24 hours)
Study: 15152270
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally
Study: 11282906
Drug: NO synthase
Normalized name: nitric oxide synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: NO synthase inhibitor Nomega-nitro-L-arginine (L-NNA) in NC
Study: 8096703
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) alone at a maintenance dose of 250 mg every 6 h
Study: 8096703
Drug: Cotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotherapy with acyclovir (ACV) at 800 mg every 6 h
Study: 31859541
Drug: Benralizumab 30
Normalized name: benralizumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benralizumab 30 mg (every 4 weeks or 8 weeks; first three doses every 4 weeks)
Study: 31300494
Drug: Oxygen 70
Normalized name: oxygen 70 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 70 L/min, airway opened by laryngoscopy
Study: 31300494
Drug: Oxygen 70
Normalized name: oxygen 70 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 70 L/min with jaw thrust
Study: 31300494
Drug: Oxygen 10
Normalized name: oxygen 10 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 10 L/min with jaw thrust
Study: 31300494
Drug: Oxygen 2
Normalized name: oxygen 2 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen 2 L/min with jaw thrust
Study: 27788026
Drug: Amitriptyline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (1 mg/kg/day)
Study: 27788026
Drug: Topiramate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (2 mg/kg/day)
Study: 23238577
Drug: STOP-Bang score
Approvals — FDA: no, EMA: no, PMDA: no
Description: STOP-Bang score ≥ 3 with serum HCO₃⁻ level ≥ 28 mmol/L
Study: 20704458
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium fast-disintegrating tablets (FDTs) 50 mg
Study: 20704458
Drug: Commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablets of diclofenac potassium 50 mg
Study: 17011374
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil (phase 1)
Study: 17011374
Drug: Dose optimization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose optimization and customized instructions (phase 2)
Study: 15001726
Drug: Interpersonal group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interpersonal group therapy
Study: 9580524
Drug: Prednisone 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 0.5 mg/kg/day
Study: 19099126
Drug: Prednisone 1
Normalized name: prednisone 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1 mg/kg/day
Study: 31652094
Drug: Lenalidomide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (25 mg orally on days 1 to 21 of a 28-day cycle)
Study: 24325111
Drug: Task-oriented approach
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented approach in combination with articulation approach
Study: 22136481
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg vitamin B12 and 400 μg folic acid daily (with 15 μg (600 IU) vitamin D included)
Study: 22136481
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (with 15 μg (600 IU) vitamin D included)
Study: 12755456
Drug: Venlafaxine (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine (225 mg daily)
Study: 12755456
Drug: Cocaine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0, 12, 25, or 50 mg)
Study: 2037706
Drug: AICA-riboside (10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside (10, 25, 50, and 100 mg/kg doses)
Study: 2037706
Drug: AICA-riboside (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside (IV and oral administration)
Study: 2037706
Drug: AICA-riboside (IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside (IV administration)
Study: 2037706
Drug: AICA-riboside (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AICA-riboside (oral administration)
Study: 21462215
Drug: Q‐ter 320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q‐ter 320 mg + creatine 340 mg
Study: 16931611
Drug: Parenteral carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral carnitine supplementation (20 mg/kg/d) at week 1 (n = 6)
Study: 16931611
Drug: Enteral carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral carnitine supplementation (20 mg/kg/d) at week 8 (n = 8)
Study: 16931611
Drug: Paired analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired analysis of parenteral at week 1 and enteral at week 8 (n = 5)
Study: 15302144
Drug: Exercise intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise intervention (compensatory training, emphasizing enhancement of visual and somatosensory function, and balance training) administered three times weekly for 12 weeks.
Study: 15302144
Drug: Placebo intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intervention (language development activities) administered three times weekly for 12 weeks.
Study: 11403983
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/day PO
Study: 11403983
Drug: Haloperidol 10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10 mg/day PO